Actively Recruiting

Age: 40Years - 69Years
All Genders
NCT07185100

Determination of the Prevalence of Unrecognized Heart Failure Among Patients at Risk in Urban Areas Across Germany Using CMR

Led by German Heart Institute · Updated on 2026-04-01

600

Participants Needed

1

Research Sites

589 weeks

Total Duration

On this page

Sponsors

G

German Heart Institute

Lead Sponsor

A

AstraZeneca

Collaborating Sponsor

AI-Summary

What this Trial Is About

Heart failure (HF) in patients at risk is often overlooked, and when detected, there is a lack of early and effective preventive interventions. The WE-CARE-HF-CMR study, conducted in large cities/metropol areas in Germany ( \> 1.000.000 inhabitants), aims to close this gap by evaluating the feasibility of a mobile, telemedicinemonitored HF-screening approach combining cardiac magnetic resonance imaging (CMR), quality of life assessment and laboratory tests as key elements in asymptomatic patients at risk. WE-CARE-HF-CMR will provide a proposal for a comprehensive, contemporary screening approach for patients at risk to develop HF tailored to the needs of the target population. This will provide important new information on the prevalence of asymptomatic HF in at-risk patients in urban versus rural areas. The results of the study will be compared with the results from the "HERZCheck'' trial, which provides data from approximately 4,500 participants in rural areas in Germany and has already been completed (NCT05122793).

CONDITIONS

Official Title

Determination of the Prevalence of Unrecognized Heart Failure Among Patients at Risk in Urban Areas Across Germany Using CMR

Who Can Participate

Age: 40Years - 69Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Asymptomatic adults aged 40 to 69 years
  • Chronic diabetes mellitus diagnosed, treated, or with elevated HbA1C
  • Renal impairment diagnosed or laboratory evidence of chronic kidney disease stage III or higher
  • Hypertension diagnosed or under treatment
  • Hypercholesterolaemia diagnosed or under treatment
  • Obesity with BMI over 30 kg/m²
  • Current or former smoker or under treatment for smoking
  • Female, male, or diverse gender
  • Ability and willingness to provide informed consent
Not Eligible

You will not qualify if you...

  • Unable to provide written informed consent
  • Diagnosed heart failure or previously detected reduced ejection fraction
  • Standard MRI exclusion criteria (e.g., pacemaker, defibrillator, aneurysm clips, metallic foreign bodies in eyes)
  • Any MRI exclusion criteria determined by the MRI laboratory
  • Haemodynamically unstable (heart rate below 45/min, systolic blood pressure below 90 mmHg)
  • Claustrophobia preventing MRI
  • Sensorineural hearing loss of 30 dB or more with tinnitus
  • Acute mental disorders requiring therapy
  • Pregnant women

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Deutsches Herzzentrum der Charité

Berlin, Germany, 13353

Actively Recruiting

Loading map...

Research Team

P

Prof. Dr. Sebastian Kelle

CONTACT

D

Dr. Gisela Thiede

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here